nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

07.04.2021 | Original Article

Value of [⁶⁸Ga]Ga-FAPI-04 imaging in the diagnosis of renal fibrosis

verfasst von: Yue Zhou, Xin Yang, Huipan Liu, Wenbin Luo, Hanxiang Liu, Taiyong Lv, Junzheng Wang, Jianhua Qin, Santao Ou, Yue Chen

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 11/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Renal fibrosis is a pathological state in the progression of chronic kidney disease. Early detection and treatment are vital to prolonging patient survival. Renal puncture examination is the gold standard for renal fibrosis, but it has several limitations. This study aims to evaluate the diagnostic performance of a novel PET radiotracer, [⁶⁸Ga]Ga-fibroblast activation protein inhibitor (FAPI)-04, which specifically images fibroblast activation protein (FAP) expression for renal fibrosis.

Methods

All patients underwent renal puncture before receiving [⁶⁸Ga]Ga-FAPI-04 PET/CT imaging. They then underwent [⁶⁸Ga]Ga-FAPI-04 PET/CT and immunochemistry examinations. The data obtained were analyzed.

Results

The [⁶⁸Ga]Ga-FAPI-04 PET/CT examination results demonstrated that almost all patients (12/13) exhibited increased radiotracer uptake. The maximum standardized uptake value (SUVmax) in patients with mild, moderate, and severe fibrosis was 3.92 ± 1.50, 5.98 ± 1.6, and 7.67 ± 2.23, respectively.

Conclusion

Compared with renal puncture examination, non-invasive imaging of FAP expression through [⁶⁸Ga]Ga-FAPI-04 PET/CT quickly demonstrates bilateral kidney conditions with high sensitivity. [⁶⁸Ga]Ga-FAPI-04 PET/CT can facilitate the evaluation of disease progression, diagnosis, and the development of a treatment plan.

Majo J, Klinkhammer BM, Boor P, Tiniakos D. Pathology and natural history of organ fibrosis. Curr Opin Pharmacol. 2019;49:82–9. https://doi.org/10.1016/j.coph.2019.09.009.CrossRefPubMed

Ruiz-Ortega M, Rayego-Mateos S, Lamas S, Ortiz A, Rodrigues-Diez RR. Targeting the progression of chronic kidney disease. Nat Rev Nephrol. 2020;16:269–88. https://doi.org/10.1038/s41581-019-0248-y.CrossRefPubMed

Pyo JY, Ahn SS, Lee LE, Choe HN, Song JJ, Park YB, et al. Efficacy of the fibrosis index for predicting end-stage renal disease in patients with antineutrophil cytoplasmic antibody-associated vasculitis. Int J Clin Pract. 2020:e13929. https://doi.org/10.1111/ijcp.13929.

Zahir Z, Wani AS, Prasad N, Jain M. Clinicopathological characteristics and predictors of poor outcome in anti-glomerular basement membrane disease - a fifteen year single center experience. Ren Fail. 2021;43:79–89. https://doi.org/10.1080/0886022X.2020.1854301.CrossRefPubMed

Zhang L, Wang F, Wang L, Wang W, Liu B, Liu J, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012;379:815–22. https://doi.org/10.1016/S0140-6736(12)60033-6.CrossRefPubMed

Tang PM, Nikolic-Paterson DJ, Lan HY. Macrophages: versatile players in renal inflammation and fibrosis. Nat Rev Nephrol. 2019;15:144–58. https://doi.org/10.1038/s41581-019-0110-2.CrossRefPubMed

Tang C, Livingston MJ, Liu Z, Dong Z. Autophagy in kidney homeostasis and disease. Nat Rev Nephrol. 2020;16:489–508. https://doi.org/10.1038/s41581-020-0309-2.CrossRefPubMedPubMedCentral

Tang S, Wang Y, Xie G, Li W, Chen Y, Liang J, et al. Regulation of Ptch1 by miR-342-5p and FoxO3 induced autophagy involved in renal fibrosis. Front Bioeng Biotechnol. 2020;8:583318. https://doi.org/10.3389/fbioe.2020.583318.CrossRefPubMedPubMedCentral

Eddy AA. Overview of the cellular and molecular basis of kidney fibrosis. Kidney Int Suppl (2011). 2014;4:2–8. https://doi.org/10.1038/kisup.2014.2.CrossRef

10.

Lipphardt M, Dihazi H, Jeon NL, Dadafarin S, Ratliff BB, Rowe DW, et al. Dickkopf-3 in aberrant endothelial secretome triggers renal fibroblast activation and endothelial-mesenchymal transition. Nephrol Dial Transplant. 2019;34:49–62. https://doi.org/10.1093/ndt/gfy100.CrossRefPubMed

11.

Yuan Q, Tan RJ, Liu Y. Myofibroblast in kidney fibrosis: origin, activation, and regulation. Adv Exp Med Biol. 2019;1165:253–83. https://doi.org/10.1007/978-981-13-8871-2_12.CrossRefPubMed

12.

Acharya PS, Zukas A, Chandan V, Katzenstein AL, Pure E. Fibroblast activation protein: a serine protease expressed at the remodeling interface in idiopathic pulmonary fibrosis. Hum Pathol. 2006;37:352–60. https://doi.org/10.1016/j.humpath.2005.11.020.CrossRefPubMed

13.

Luo Y, Pan Q, Zhang W. IgG4-related disease revealed by ⁶⁸Ga-FAPI and 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2019;46:2625–6. https://doi.org/10.1007/s00259-019-04478-2.CrossRefPubMed

14.

Hao B, Wu X, Pang Y, Sun L, Wu H, Huang W, et al. [(18)F]FDG and ([68)Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of tuberculous lesions. Eur J Nucl Med Mol Imaging. 2021;48:651–2. https://doi.org/10.1007/s00259-020-04941-5.CrossRefPubMed

15.

Chen H, Pang Y, Wu J, Zhao L, Hao B, Wu J, et al. Comparison of [⁽⁶⁸⁾Ga]Ga-DOTA-FAPI-04 and [(18)F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur J Nucl Med Mol Imaging. 2020;47:1820–32. https://doi.org/10.1007/s00259-020-04769-z.CrossRefPubMed

16.

Luo Y, Pan Q, Zhang W, Li F. Intense FAPI uptake in inflammation may mask the tumor activity of pancreatic cancer in ⁶⁸Ga-FAPI PET/CT. Clin Nucl Med. 2020;45:310–1. https://doi.org/10.1097/RLU.0000000000002914.CrossRefPubMed

17.

Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214:199–210. https://doi.org/10.1002/path.2277.CrossRefPubMedPubMedCentral

18.

Liu Y. Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol. 2011;7:684–96. https://doi.org/10.1038/nrneph.2011.149.CrossRefPubMedPubMedCentral

19.

Conway B, Hughes J. Cellular orchestrators of renal fibrosis. QJM. 2012;105:611–5. https://doi.org/10.1093/qjmed/hcr235.CrossRefPubMed

20.

Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int. 2006;69:213–7. https://doi.org/10.1038/sj.ki.5000054.CrossRefPubMed

21.

Nakaigawa N, Kondo K, Kaneta T, Tateishi U, Minamimoto R, Namura K, et al. FDG PET/CT after first molecular targeted therapy predicts survival of patients with renal cell carcinoma. Cancer Chemother Pharmacol. 2018;81:739–44. https://doi.org/10.1007/s00280-018-3542-7.CrossRefPubMed

22.

Sonni I, Lee-Felker S, Memarzadeh S, Quinn MM, Mona CE, Luckerath K, et al. ⁽⁶⁸⁾Ga-FAPi-46 diffuse bilateral breast uptake in a patient with cervical cancer after hormonal stimulation. Eur J Nucl Med Mol Imaging. 2020. https://doi.org/10.1007/s00259-020-04947-z.

23.

Wang L, Zhang Z, Zhao Z, Yan C, Fang W. ⁽⁶⁸⁾Ga-FAPI right heart uptake in a patient with idiopathic pulmonary arterial hypertension. J Nucl Cardiol. 2020. https://doi.org/10.1007/s12350-020-02407-7.

24.

Jiang K, Ferguson CM, Lerman LO. Noninvasive assessment of renal fibrosis by magnetic resonance imaging and ultrasound techniques. Transl Res. 2019;209:105–20. https://doi.org/10.1016/j.trsl.2019.02.009.CrossRefPubMedPubMedCentral

25.

Gao J, Rubin JM, Weitzel W, Lee J, Dadhania D, Kapur S, et al. Comparison of ultrasound corticomedullary strain with Doppler parameters in assessment of renal allograft interstitial fibrosis/tubular atrophy. Ultrasound Med Biol. 2015;41:2631–9. https://doi.org/10.1016/j.ultrasmedbio.2015.06.009.CrossRefPubMed

26.

O’Neill WC. Sonographic evaluation of renal failure. Am J Kidney Dis. 2000;35:1021–38. https://doi.org/10.1016/s0272-6386(00)70036-9.CrossRefPubMed

27.

Nijssen EC, Rennenberg R, Nelemans P, van Ommen V, Wildberger JE. Post-contrast acute kidney injury and intravenous prophylactic hydration: an update. Rofo. 2021;193:151–9. https://doi.org/10.1055/a-1248-9178.CrossRefPubMed

28.

Zhang XQ, Li X, Zhou WQ, Liu X, Huang JL, Zhang YY, et al. Serum Lysyl oxidase is a potential diagnostic biomarker for kidney fibrosis. Am J Nephrol. 2020;51:907–18. https://doi.org/10.1159/000509381.CrossRefPubMed

29.

Basturk T, Ojalvo D, Mazi EE, Hasbal NB, Ozagari AA, Ahbap E, et al. Pentraxin-2 is associated with renal fibrosis in patients undergoing renal biopsy. Clinics (Sao Paulo). 2020;75:e1809. https://doi.org/10.6061/clinics/2020/e1809.CrossRefPubMedCentral

30.

Chen P, Yang Q, Li X, Qin Y. Potential association between elevated serum human epididymis protein 4 and renal fibrosis: a systemic review and meta-analysis. Medicine (Baltimore). 2017;96:e7824. https://doi.org/10.1097/MD.0000000000007824.CrossRefPubMedCentral

31.

Nijssen EC, Rennenberg R, Nelemans P, van Ommen V, Wildberger JE. Post-contrast acute kidney injury and intravenous prophylactic hydration: an update. Rofo. 2020. https://doi.org/10.1055/a-1248-9178.

32.

Luciano RL, Moeckel GW. Update on the native kidney biopsy: core curriculum 2019. Am J Kidney Dis. 2019;73:404–15. https://doi.org/10.1053/j.ajkd.2018.10.011.CrossRefPubMed

33.

Bauer S, Jendro MC, Wadle A, Kleber S, Stenner F, Dinser R, et al. Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes. Arthritis Res Ther. 2006;8:R171. https://doi.org/10.1186/ar2080.CrossRefPubMedPubMedCentral

34.

Xu T, Zhao Y, Ding H, Cai L, Zhou Z, Song Z, et al. [⁽⁶⁸⁾Ga]Ga-DOTA-FAPI-04 PET/CT imaging in a case of prostate cancer with shoulder arthritis. Eur J Nucl Med Mol Imaging. 2020. https://doi.org/10.1007/s00259-020-05028-x.

35.

Liu H, Wang Y, Zhang W, Cai L, Chen Y. Elevated [⁽⁶⁸⁾Ga]Ga-DOTA-FAPI-04 activity in degenerative osteophyte in a patient with lung cancer. Eur J Nucl Med Mol Imaging. 2020. https://doi.org/10.1007/s00259-020-05090-5.

36.

Luo Y, Pan Q, Xu H, Zhang R, Li J, Li F. Active uptake of ⁽⁶⁸⁾Ga-FAPI in Crohn’s disease but not in ulcerative colitis. Eur J Nucl Med Mol Imaging. 2020. https://doi.org/10.1007/s00259-020-05129-7.

37.

Zhao L, Gu J, Fu K, Lin Q, Chen H. ⁶⁸Ga-FAPI PET/CT in assessment of liver nodules in a cirrhotic patient. Clin Nucl Med. 2020;45:e430–e2. https://doi.org/10.1097/RLU.0000000000003015.CrossRefPubMed

38.

Heckmann MB, Reinhardt F, Finke D, Katus HA, Haberkorn U, Leuschner F, et al. Relationship between cardiac fibroblast activation protein activity by positron emission tomography and cardiovascular disease. Circ Cardiovasc Imaging. 2020;13:e010628. https://doi.org/10.1161/CIRCIMAGING.120.010628.CrossRefPubMedPubMedCentral

39.

Hao B, Wu X, Pang Y, Sun L, Wu H, Huang W, et al. [⁽¹⁸⁾F]FDG and [⁽⁶⁸⁾Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of tuberculous lesions. Eur J Nucl Med Mol Imaging. 2020. https://doi.org/10.1007/s00259-020-04941-5.

40.

Schmidkonz C, Rauber S, Atzinger A, Agarwal R, Gotz TI, Soare A, et al. Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging. Ann Rheum Dis. 2020;79:1485–91. https://doi.org/10.1136/annrheumdis-2020-217408.CrossRefPubMed

Titel: Value of [68Ga]Ga-FAPI-04 imaging in the diagnosis of renal fibrosis
verfasst von: Yue Zhou
Xin Yang
Huipan Liu
Wenbin Luo
Hanxiang Liu
Taiyong Lv
Junzheng Wang
Jianhua Qin
Santao Ou
Yue Chen
Publikationsdatum: 07.04.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 11/2021
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-021-05343-x

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Value of [⁶⁸Ga]Ga-FAPI-04 imaging in the diagnosis of renal fibrosis

Abstract

Purpose

Methods

Results

Conclusion

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2021

Kinetic analysis and optimisation of 18F-rhPSMA-7.3 PET imaging of prostate cancer

[18F]-C-SNAT4: an improved caspase-3-sensitive nanoaggregation PET tracer for imaging of tumor responses to chemo- and immunotherapies

Image quality and lesion detectability in low-dose pediatric 18F-FDG scans using total-body PET/CT

[18F]FDG PET radiomics to predict disease-free survival in cervical cancer: a multi-scanner/center study with external validation

Cell-free DNA concentration and fragment size fraction correlate with FDG PET/CT-derived parameters in NSCLC patients

Predicting tumor response and prognosis to neoadjuvant chemotherapy in esophageal squamous cell carcinoma patients using PERCIST: a multicenter study in Japan